利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

64 records (took 0.019 seconds)

    PLURIPOTENT HUMAN ADIPOSE ADULT STEM CELLS: ISOLATION, CHARACTERIZATION AND CLINICAL IMPLICATIONS
    4.
    发明申请
    PLURIPOTENT HUMAN ADIPOSE ADULT STEM CELLS: ISOLATION, CHARACTERIZATION AND CLINICAL IMPLICATIONS 审中-公开
    PLUIPOTENT人体成熟干细胞：分离，特征和临床意义

    公开(公告)号：WO2014190150A1

    公开(公告)日：2014-11-27

    申请号：PCT/US2014/039137

    申请日：2014-05-22

    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

    Inventor： CHAZENBALK, Gregorio

    IPC: C12N5/0775 ,  A61K35/12 ,  A61P3/08 ,  A61P25/00 ,  A61P31/00 ,  A61P35/00 ,  A61P37/00

    CPC classification number: C12N5/0667 ,  A61K35/28 ,  C12N5/0607 ,  C12N2500/02 ,  C12N2501/734 ,  C12N2506/1384

    Abstract: Methods for the efficient isolation and use of pluripotent adipose-derived stem cells (PASCs) are provided. In certain embodiments the methods involve providing an adipose tissue sample from which the stromal vascular fraction is co-cultured with the adipocyte fraction. PASCs can be isolated with a high degree of purification without requiring an additional cell enrichment process (e.g. cell sorting). PASCs and their conditioned media can be used for tissue regeneration within hours of harvesting the adipose tissue, and without requiring cell expansion. PASCs can grow as floating individual cells, as clusters of cells, or attached to surface(s) of the culture vessel. PASCs do not produce teratomas in vivo, nor do they induce immunorejection upon transplantation, and they achieve a high efficiency in grafting. The cells and compositions can be used for cell therapy and to screen new drugs.

    Abstract translation: 提供了有效分离和使用多能脂肪干细胞（PASCs）的方法。 在某些实施方案中，所述方法涉及提供脂肪组织样品，其中基质血管部分与脂肪细胞部分共培养。 可以用高纯度的纯化分离PASC，而不需要另外的细胞富集过程（例如细胞分选）。 PASCs及其条件培养基可以在收获脂肪组织数小时内用于组织再生，而不需要细胞扩增。 PASCs可以作为漂浮的单个细胞，如细胞簇生长，或附着于培养容器的表面。 PASCs在体内不产生畸胎瘤，也不会在移植时诱导免疫反应，并且它们在移植中获得高效率。 细胞和组合物可用于细胞治疗和筛选新药。

    MODULATING IMMUNE CELL ACTIVITY USING CYTOKINE-INDUCED SRC HOMOLOGY 2 AND/OR HIGH TEMPERATURE REQUIREMENT A-1
    7.
    发明申请
    MODULATING IMMUNE CELL ACTIVITY USING CYTOKINE-INDUCED SRC HOMOLOGY 2 AND/OR HIGH TEMPERATURE REQUIREMENT A-1 审中-公开
    使用细胞因子诱导的SRC同种异体2和/或高温要求调节免疫细胞活性A-1

    公开(公告)号：WO2012078540A1

    公开(公告)日：2012-06-14

    申请号：PCT/US2011/063375

    申请日：2011-12-06

    Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES ,  PALMER, Douglas C. ,  RESTIFO, Nicholas P.

    Inventor： PALMER, Douglas C. ,  RESTIFO, Nicholas P.

    IPC: C12Q1/68

    CPC classification number: C12N5/0636 ,  C12N2501/734 ,  C12N2501/998

    Abstract: The invention provides a peripheral blood cell (PBC) comprising a high temperature requirement serine peptidase 1 (HTRA1)/ htra1 activator, a host cell comprising a cytokine-induced Src homology 2 protein (CIS) /cish inhibitor and a HTRA1/ htra1 activator, a host cell comprising an anti-cish shMIR comprising SEQ ID NO: 3 or 4, and related populations of cells, pharmaceutical compositions, methods of treating or preventing cancer or a chronic infectious disease in a mammal, and methods of increasing T cell activity in a mammal. The invention also provides a host cell comprising a HTRA1/ htra1 inhibitor and a CIS /cish activator, a PBC comprising a HTRA1/ htra1 inhibitor, and related populations of cells, pharmaceutical compositions, methods of treating or preventing an auto- and/or allo-immune disease in a mammal, and methods of suppressing T cell activity in a mammal.

    Abstract translation: 本发明提供了包含高温要求丝氨酸肽酶1（HTRA1）/ htra1激活剂的外周血细胞（PBC），包含细胞因子诱导的Src同源性2蛋白（CIS）/ cish抑制剂和HTRA1 / htra1激活剂的宿主细胞， 包含包含SEQ ID NO：3或4的抗结皮shMIR和哺乳动物的相关的细胞群，药物组合物，治疗或预防癌症或慢性感染性疾病的方法的宿主细胞，以及增加T细胞活性的方法 哺乳动物 本发明还提供了包含HTRA1 / htra1抑制剂和CIS / cish激活剂的宿主细胞，包含HTRA1 / htra1抑制剂的PBC和相关的细胞群，药物组合物，治疗或预防自身和/或同种异体的方法 哺乳动物中的免疫性疾病，抑制哺乳动物T细胞活性的方法。

    METHOD OF DERIVING PROGENITOR CELL LINE
    10.
    发明申请
    METHOD OF DERIVING PROGENITOR CELL LINE 审中-公开
    衍生细胞系的方法

    公开(公告)号：WO2007027157A1

    公开(公告)日：2007-03-08

    申请号：PCT/SG2006/000233

    申请日：2006-08-15

    Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH ,  LIM, Sai Kiang ,  LYE, Elias

    Inventor： LIM, Sai Kiang ,  LYE, Elias

    IPC: C12N5/06 ,  C12N5/08 ,  G01N33/50

    CPC classification number: C12N5/0603 ,  C12N5/0662 ,  C12N2501/115 ,  C12N2501/135 ,  C12N2501/734 ,  C12N2502/1352 ,  C12N2506/02 ,  C12Q1/6809 ,  G01N33/5044

    Abstract: We disclose a method comprising: (a) providing an embryonic stem (ES) cell; and (b) establishing a progenitor cell line from the embryonic stem cell; in which the progenitor cell line is selected based on its ability to self-renew. Preferably, the method selects against somatic cells based on their inability to self-renew. Preferably, the progenitor cell line is derived or established in the absence of co-culture, preferably in the absence of feeder cells, which preferably selects against embryonic stem cells. Optionally, the method comprises (d) deriving a differentiated cell from the progenitor cell line.

    Abstract translation: 我们公开了一种方法，包括：（a）提供胚胎干（ES）细胞; 和（b）从胚胎干细胞建立祖细胞系; 其中根据其自我更新能力选择祖细胞系。 优选地，该方法基于它们不能自我更新而针对体细胞进行选择。 优选地，在不存在共培养的情况下，优选在不存在饲养细胞的情况下衍生或建立祖细胞系，其优选选择抗胚胎干细胞。 任选地，该方法包括（d）从祖细胞系衍生分化的细胞。

Patent Agency Ranking